Zobrazeno 1 - 10
of 34
pro vyhledávání: '"John J. Engelhardt"'
Autor:
Peter S. Lee, Katherine G. MacDonald, Evan Massi, Pamela V. Chew, Christine Bee, Padma Perkins, Bryant Chau, Kent Thudium, Jack Lohre, Pradyot Nandi, Ekaterina G. Deyanova, Ishita Barman, Olafur Gudmundsson, Gavin Dollinger, Tim Sproul, John J. Engelhardt, Pavel Strop, Arvind Rajpal
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Although therapeutically efficacious, ipilimumab can exhibit dose-limiting toxicity that prevents maximal efficacious clinical outcomes and can lead to discontinuation of treatment. We hypothesized that an acidic pH-selective ipilimumab (pH Ipi), whi
Externí odkaz:
https://doaj.org/article/691eb159503a4399a519acfc7748ae85
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 102K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a78834acb42bbd09b0c532e9cc23c8a
https://doi.org/10.1158/2326-6066.22536218.v1
https://doi.org/10.1158/2326-6066.22536218.v1
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3. Representative FACS plots for pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f18a019212133139aeaed992d67891
https://doi.org/10.1158/2326-6066.22536215
https://doi.org/10.1158/2326-6066.22536215
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
Antitumor activity of CTLA-4 antibody blockade is thought to be mediated by interfering with the negative regulation of T-effector cell (Teff) function resulting from CTLA-4 engagement by B7-ligands. In addition, a role for CTLA-4 on regulatory T cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6011009163f523d370deaf09ace35c72
https://doi.org/10.1158/2326-6066.c.6548072
https://doi.org/10.1158/2326-6066.c.6548072
Autor:
Alan J. Korman, Mohan Srinivasan, Timothy Chen, Karla A. Henning, Michael Quigley, John J. Engelhardt, Mark J. Selby
PDF file - 94K, Supplemental Table S1. Binding affinities of anti-CTLA-4 isotypes to murine FcγR proteins as assessed by surface plasmon resonance. Supplemental Table S2. Summary of pharmacokinetic parameters of anti-CTLA4 isotypes following a singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9402efd30c653fdbc8ddf8b449235fcc
https://doi.org/10.1158/2326-6066.22536212.v1
https://doi.org/10.1158/2326-6066.22536212.v1
Autor:
Mark J Selby, John J Engelhardt, Robert J Johnston, Li-Sheng Lu, Minhua Han, Kent Thudium, Dapeng Yao, Michael Quigley, Jose Valle, Changyu Wang, Bing Chen, Pina M Cardarelli, Diann Blanset, Alan J Korman
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0161779 (2016)
The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with met
Externí odkaz:
https://doaj.org/article/e4cbf86cb6a84748be5b341a365cb284
Autor:
Alyza M. Skaist, Christina M. Kochel, Thomas R. Nirschl, John J. Engelhardt, Ali Ghasemzadeh, Linda A. Snyder, Robert J. Johnston, Alan J. Korman, Anuj Gupta, Hui Jiang, Daniel H. Hovelson, Scott A. Tomlins, Alexander T. Pearson, Zachary T. Freeman, Jingyi Zhai, Charles G. Drake, Ruth Y. Lan, Mark J. Selby, Sarah J. Wheelan, Srinivasan Yegnasubramanian
Publikováno v:
J Clin Invest
Despite advancements in targeting the immune checkpoints program cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte–associated protein 4 (CTLA-4) for cancer immunotherapy, a large number of patients and cance
Autor:
Alvaro Teijeira, Arantza Azpilikueta, Emanuela Sega, James West, Ignacio Melero, Iñaki Etxeberria, Maria C. Ochoa, Elixabet Bolaños, Maria Rodriguez, John J. Engelhardt, Saray Garasa, Bryan Irving, Alba Yanguas, Marcia Belvin, Kimberly Ann Tipton, Bruce Howng, Ana Melero, Olga Vasiljeva, Li Mei, Assunta Cirella, Korman Alan J, Miguel F. Sanmamed, Irene Olivera, William M. Kavanaugh
Publikováno v:
Proc Natl Acad Sci U S A
Costimulation via CD137 (4-1BB) enhances antitumor immunity mediated by cytotoxic T lymphocytes. Anti-CD137 agonist antibodies elicit mild liver inflammation in mice, and the maximum tolerated dose of Urelumab, an anti-human CD137 agonist monoclonal
Autor:
Wagtmann Nicolai, Jean-Marie Cuillerott, Gutierrez Eva, Colin LaCroix, John J. Engelhardt, Bigelow Mitchell, Philip Ansumana Hull, Grinberg Asya, Cheung Ann, Lynn Markowitz, Steve O'Neil, Patrick Kirby, Michael Naill
Publikováno v:
Cancer Research. 81:1714-1714
Background: Interleukin 12 (IL-12) is a proinflammatory cytokine that plays a central role in regulating both innate and adaptive antitumor immune responses. Clinically, administration of recombinant human IL-12 (rhIL-12) has been limited by a short
Autor:
Robert F, Graziano, John J, Engelhardt
Publikováno v:
Current topics in microbiology and immunology. 423
Monoclonal antibodies can mediate antitumor activity by multiple mechanisms. They can bind directly to tumor receptors resulting in tumor cell death, or can bind to soluble growth factors, angiogenic factors, or their cognate receptors blocking signa